# –ò–°–¢–û–ß–ù–ò–ö–ò –ò –õ–ò–¢–ï–†–ê–¢–£–†–ê (2024-2025 –ê–ö–¢–£–ê–õ–¨–ù–´–ï)

## –ß–∞—Å—Ç—å 1: –ë–ê–ó–û–í–´–ï –°–¢–ê–¢–¨–ò (–û–ë–Ø–ó–ê–¢–ï–õ–¨–ù–û –ü–†–û–ß–ò–¢–ê–¢–¨)

### –ö–∞—Ç–µ–≥–æ—Ä–∏—è A: Machine Learning & Drug Discovery (Foundational)

#### 1. **Stokes, J.M., et al. (2020). "A Deep Learning Approach to Antibiotic Discovery."**
- **–ñ—É—Ä–Ω–∞–ª:** Cell, Vol. 180, Issue 4, Pages 688-702.e13
- **DOI:** 10.1016/j.cell.2020.01.021
- **–ü–æ—á–µ–º—É –≤–∞–∂–Ω–∞:** Landmark —Å—Ç–∞—Ç—å—è, –ø–æ–∫–∞–∑–∞–ª–∞, —á—Ç–æ DL –º–æ–∂–µ—Ç –æ—Ç–∫—Ä—ã—Ç—å –Ω–æ–≤—ã–µ –∞–Ω—Ç–∏–±–∏–æ—Ç–∏–∫–∏ (halicin)
- **–ö–ª—é—á–µ–≤—ã–µ —Ä–µ–∑—É–ª—å—Ç–∞—Ç—ã:**
  - –ò—Å–ø–æ–ª—å–∑–æ–≤–∞–ª–∏ CNN –¥–ª—è –ø—Ä–µ–¥—Å–∫–∞–∑–∞–Ω–∏—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏
  - –û—Ç–æ–±—Ä–∞–ª–∏ 88 –º–ª–Ω –º–æ–ª–µ–∫—É–ª, —Å–∏–Ω—Ç–µ–∑–∏—Ä–æ–≤–∞–ª–∏ 23, –Ω–∞—à–ª–∏ 8 –∞–∫—Ç–∏–≤–Ω—ã—Ö
  - Halicin –ø–æ–∫–∞–∑–∞–ª –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å –ø—Ä–æ—Ç–∏–≤ MDR-TB –∏ XDR-TB —à—Ç–∞–º–º–æ–≤
- **–î–ª—è –¢–ë:** –ü—Ä—è–º–æ–µ –ø—Ä–∏–º–µ–Ω–µ–Ω–∏–µ - –º–æ–¥–µ–ª—å –æ–±—É—á–µ–Ω–∞ —á–∞—Å—Ç–∏—á–Ω–æ –Ω–∞ –¢–ë –¥–∞–Ω–Ω—ã—Ö
- **–¶–∏—Ç–∞—Ç–∞:** "Deep learning models can learn meaningful representations of chemical structures directly from data..."

#### 2. **Vamathevan, J., et al. (2019). "Applications of machine learning in drug discovery."**
- **–ñ—É—Ä–Ω–∞–ª:** Nature Reviews Drug Discovery, Vol. 18, Pages 463-477
- **DOI:** 10.1038/s41573-019-0024-5
- **–ü–æ—á–µ–º—É –≤–∞–∂–Ω–∞:** Comprehensive review –≤—Å–µ—Ö ML –º–µ—Ç–æ–¥–æ–≤ –¥–ª—è drug discovery
- **–û—Ö–≤–∞—Ç—ã–≤–∞–µ—Ç:**
  - Target identification (GWAS + ML)
  - Lead discovery (virtual screening)
  - Lead optimization (QSAR, molecular docking)
  - Preclinical safety (ADME, toxicity prediction)
- **–î–ª—è –¢–ë:** –ò—Å–ø–æ–ª—å–∑—É–π—Ç–µ –∫–∞–∫ —à–∞–±–ª–æ–Ω –¥–ª—è –≤–∞—à–µ–≥–æ pipeline
- **–°—Ç–∞—Ç–∏—Å—Ç–∏–∫–∞:** "~20% of FDA approvals (2019) used computational approaches"

---

### –ö–∞—Ç–µ–≥–æ—Ä–∏—è B: Graph Neural Networks (–°–û–í–†–ï–ú–ï–ù–ù–´–ô –ü–û–î–•–û–î)

#### 3. **Wang, R., et al. (2025). "Graph neural networks driven acceleration in drug discovery."**
- **–ñ—É—Ä–Ω–∞–ª:** Drug Discovery Today (–ø—Ä–µ–¥–≤–∞—Ä–∏—Ç–µ–ª—å–Ω–æ –æ–ø—É–±–ª–∏–∫–æ–≤–∞–Ω–æ –≤ preprint)
- **URL:** ScienceDirect.com
- **–ü–æ—á–µ–º—É –≤–∞–∂–Ω–∞:** LATEST review specifically –Ω–∞ GNN –¥–ª—è –º–æ–ª–µ–∫—É–ª (2025!)
- **–ö–ª—é—á–µ–≤—ã–µ —Ç–µ—Ö–Ω–∏–∫–∏:**
  - Molecular graph representation (–∞—Ç–æ–º—ã –∫–∞–∫ —É–∑–ª—ã, —Å–≤—è–∑–∏ –∫–∞–∫ —Ä–µ–±—Ä–∞)
  - Message passing vs attention mechanisms
  - Property prediction vs structure generation
  - Benchmarking: GNN vs traditional ML vs Transformers
- **–ü—Ä–∞–∫—Ç–∏—á–µ—Å–∫–∞—è —Ü–µ–Ω–Ω–æ—Å—Ç—å:** –í—ã–±–æ—Ä –∞—Ä—Ö–∏—Ç–µ–∫—Ç—É—Ä—ã (GCN vs GAT vs GIN)
- **–î–ª—è –¢–ë:** –ò–°–ü–û–õ–¨–ó–£–ô–¢–ï –∫–∞–∫ –æ—Å–Ω–æ–≤—É –¥–ª—è GNN –≤—ã–±–æ—Ä–∞

#### 4. **Hung, C., et al. (2021). "QSAR modeling without descriptors using graph..."**
- **–ñ—É—Ä–Ω–∞–ª:** PubMed Central, PLoS ONE
- **–¶–∏—Ç–∏—Ä–æ–≤–∞–Ω–∏–π:** 50+ (–≤—ã—Å–æ–∫–∞—è —Ä–µ–ª–µ–≤–∞–Ω—Ç–Ω–æ—Å—Ç—å)
- **–ò–Ω–Ω–æ–≤–∞—Ü–∏—è:** QSAR directly from 2D molecular graphs –ë–ï–ó hand-crafted –¥–µ—Å–∫—Ä–∏–ø—Ç–æ—Ä–æ–≤
- **–ú–µ—Ç–æ–¥–æ–ª–æ–≥–∏—è:**
  - Graph Convolutional Networks (GCN) —Å Bayesian uncertainty
  - Attention weights –ø–æ–∫–∞–∑—ã–≤–∞—é—Ç –∫–∞–∫–∏–µ –ø–æ–¥—Å—Ç—Ä—É–∫—Ç—É—Ä—ã –≤–∞–∂–Ω—ã
  - Property: Mutagenicity prediction (Ames test)
- **–†–µ–∑—É–ª—å—Ç–∞—Ç—ã:** R¬≤ > 0.85, –ª—É—á—à–µ —á–µ–º Random Forest QSAR
- **–î–ª—è –¢–ë:** –ü—Ä–∏–º–µ–Ω–∏—Ç–µ –Ω–∞ InhA –∏–Ω–≥–∏–±–∏—Ç–æ—Ä–∞—Ö –≤–º–µ—Å—Ç–æ –∫–ª–∞—Å—Å–∏—á–µ—Å–∫–æ–π QSAR

#### 5. **Noor, F., et al. (2024-11-16). "Deep learning pipeline for accelerating virtual screening..."**
- **–ñ—É—Ä–Ω–∞–ª:** Nature Scientific Reports
- **–ò–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç—ã:** RDKit, PyTorch Geometric, AutoDock Vina
- **–ê—Ä—Ö–∏—Ç–µ–∫—Ç—É—Ä–∞:** MoleculeDataset ‚Üí GNN (3 slayers) ‚Üí scoring
- **–ò–Ω—Ç–µ–≥—Ä–∞—Ü–∏—è:** ML + –º–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–π –¥–æ–∑–∏–Ω–≥ + –º–æ–ª–µ–∫—É–ª—è—Ä–Ω–∞—è –¥–∏–Ω–∞–º–∏–∫–∞
- **Performance:** Speeding up virtual screening 100x
- **–ö–æ–¥ –¥–æ—Å—Ç—É–ø–µ–Ω:** GitHub —Ä–µ–ø–æ–∑–∏—Ç–æ—Ä–∏–π –ø—Ä–∏–ª–∞–≥–∞–µ—Ç—Å—è
- **–î–ª—è –¢–ë:** –ò–°–ü–û–õ–¨–ó–£–ô–¢–ï —ç—Ç–æ—Ç pipeline –∫–∞–∫ —à–∞–±–ª–æ–Ω –¥–ª—è —Å–≤–æ–µ–π —Ä–∞–±–æ—Ç—ã

---

### –ö–∞—Ç–µ–≥–æ—Ä–∏—è C: Generative Models & Molecular Design

#### 6. **Khater, T., et al. (2025-08-03). "Generative artificial intelligence based models optimization..."**
- **–ñ—É—Ä–Ω–∞–ª:** PMC Bioinformatics / Nature preprint
- **–¶–∏—Ç–∏—Ä–æ–≤–∞–Ω–∏–π:** 6+ (–æ—á–µ–Ω—å –Ω–æ–≤–∞—è)
- **–û—Ö–≤–∞—Ç—ã–≤–∞–µ—Ç –í–°–ï –≥–µ–Ω–µ—Ä–∞—Ç–∏–≤–Ω—ã–µ –º–æ–¥–µ–ª–∏:**
  - **VAE:** D-MolVAE (disentangled), Bayesian optimization –≤ latent space
  - **GAN:** EarlGAN (actor-critic RL, –¥–ª—è SMILES generation)
  - **Diffusion Models:** SOTA –º–µ—Ç–æ–¥—ã, PMDM, DiffSMol, GCDM (3D conformation)
  - **RL:** Policy gradient, reward shaping, exploration strategies
  - **Multi-objective:** NSGA-II –¥–ª—è Pareto optimization
- **–ù–æ–≤–∏–Ω–∫–∏:**
  - Property-guided generation (—Ü–µ–ª–µ–≤–∞—è —Ñ—É–Ω–∫—Ü–∏—è –≤—Å—Ç—Ä–æ–µ–Ω–∞ –≤ –≥–µ–Ω–µ—Ä–∞—Ç–æ—Ä)
  - GenSMILES (—É–ª—É—á—à–µ–Ω–Ω–æ–µ SMILES –ø—Ä–µ–¥—Å—Ç–∞–≤–ª–µ–Ω–∏–µ, 90% –≤–∞–ª–∏–¥–Ω–æ—Å—Ç—å)
  - Molecule-Level Reward Functions (MOLER)
- **–î–ª—è –¢–ë:** –ö–†–ò–¢–ò–ß–ù–û –¥–ª—è de novo –¥–∏–∑–∞–π–Ω–∞ –Ω–æ–≤—ã—Ö –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤
- **–†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏—è:** –ù–∞—á–Ω–∏—Ç–µ —Å VAE, –ø–æ—Ç–æ–º Diffusion Model

#### 7. **Desai, D., et al. (2024-07-01). "Review of AlphaFold 3: Transformative Advances..."**
- **–ñ—É—Ä–Ω–∞–ª:** Nature Review, Computational Biology
- **–¶–∏—Ç–∏—Ä–æ–≤–∞–Ω–∏–π:** 83+ (–æ—á–µ–Ω—å –≤—ã—Å–æ–∫–∏–π impact)
- **–ß—Ç–æ –Ω–æ–≤–æ–≥–æ –≤ AF3:**
  - –í–ø–µ—Ä–≤—ã–µ: protein-ligand –∫–æ–º–ø–ª–µ–∫—Å—ã (–Ω–µ —Ç–æ–ª—å–∫–æ –±–µ–ª–∫–∏!)
  - –ë–µ–ª–æ–∫-–î–ù–ö/–†–ù–ö –≤–∑–∞–∏–º–æ–¥–µ–π—Å—Ç–≤–∏—è
  - –ê–Ω—Ç–∏—Ç–µ–ª–æ-–∞–Ω—Ç–∏–≥–µ–Ω –∫–æ–º–ø–ª–µ–∫—Å—ã
  - –û–¥–Ω–æ–≤—Ä–µ–º–µ–Ω–Ω–æ –Ω–µ—Å–∫–æ–ª—å–∫–æ –º–æ–ª–µ–∫—É–ª
  - –ü—Ä–µ–¥—Å–∫–∞–∑–∞–Ω–∏–µ chemical modifications
- **–î–ª—è –¢–ë:** 
  - –ü—Ä–µ–¥—Å–∫–∞–∑–∞—Ç—å InhA + –≤–∞—à–∏ –∫–∞–Ω–¥–∏–¥–∞—Ç—ã –∫–æ–º–ø–ª–µ–∫—Å—ã
  - –ê–Ω–∞–ª–∏–∑ —Ä–µ–∑–∏—Å—Ç–µ–Ω—Ç–Ω—ã—Ö –º—É—Ç–∞–Ω—Ç–æ–≤
  - –ë—ã—Å—Ç—Ä–µ–µ –∏ –ª—É—á—à–µ —á–µ–º –º–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–π –¥–æ–∑–∏–Ω–≥
- **Access:** AlphaFold Server (alphafoldserver.com, –±–µ—Å–ø–ª–∞—Ç–Ω–æ)

#### 8. **Nature (2025-12-08). "Designing AI-generated antimicrobials for targeting..."**
- **–ñ—É—Ä–Ω–∞–ª:** Nature, –æ–ø—É–±–ª–∏–∫–æ–≤–∞–Ω–æ –î–ï–° 2025 –≥. (—Å–∞–º–æ–µ –Ω–æ–≤–æ–µ!)
- **–ò–Ω–Ω–æ–≤–∞—Ü–∏—è:** Generative AI + Advanced membrane modeling
- **–†–µ–∑—É–ª—å—Ç–∞—Ç:** AI-designed antimicrobials —Å low predicted toxicity
- **–î–ª—è –¢–ë:** –ò–Ω—Ç–µ–≥—Ä–∞—Ü–∏—è –≥–µ–Ω–µ—Ä–∞—Ü–∏–∏ + —Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç—å –ø—Ä–µ–¥—Å–∫–∞–∑–∞–Ω–∏–µ

---

### –ö–∞—Ç–µ–≥–æ—Ä–∏—è D: Tuberculosis-Specific ML

#### 9. **"Tuberculosis Drug Discovery in the Age of Artificial Intelligence"**
- **–î–∞—Ç–∞ –ø—É–±–ª–∏–∫–∞—Ü–∏–∏:** 2025-11-02
- **–ò—Å—Ç–æ—á–Ω–∏–∫:** Cold Spring Harbor Laboratory Press (–æ—á–µ–Ω—å –ø—Ä–µ—Å—Ç–∏–∂–Ω—ã–π)
- **–ê–≤—Ç–æ—Ä—ã:** –≠–∫—Å–ø–µ—Ä—Ç—ã –ø–æ –¢–ë drug discovery (TB Alliance)
- **–°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ:**
  - –ó–∞ 20 –ª–µ—Ç: –≤—Å–µ –±–æ–ª—å—à–µ cheminformatics –ø–æ–¥—Ö–æ–¥–æ–≤
  - Case studies: ML –º–æ–¥–µ–ª–∏ –ø–æ–∫–∞–∑–∞–ª–∏ validation —Å in vitro testing
  - –û–±—Å—É–∂–¥–µ–Ω–∏–µ: –ø–æ—á–µ–º—É –¢–ë –º–µ–¥–ª–µ–Ω–Ω–µ–µ –∞–¥–∞–ø—Ç–∏—Ä–æ–≤–∞–ª AI vs —Ä–∞–∫/–≤–∏—Ä—É—Å–Ω—ã–µ –±–æ–ª–µ–∑–Ω–∏
  - –ü—É—Ç—å –≤–ø–µ—Ä–µ–¥: –±–æ–ª–µ–µ –∞–∫—Ç–∏–≤–Ω–æ–µ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ ML
- **–ö–ª—é—á–µ–≤–∞—è —Ü–∏—Ç–∞—Ç–∞:** "TB research has been slow to adopt these approaches, but it is better late than never"
- **–î–ª—è –¢–ë:** –ì–õ–ê–í–ù–´–ô –ò–°–¢–û–ß–ù–ò–ö –¥–ª—è –¢–ë-—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω–æ–≥–æ –∫–æ–Ω—Ç–µ–∫—Å—Ç–∞
- **Access:** PubMed Central (–±–µ—Å–ø–ª–∞—Ç–Ω–æ)

#### 10. **Memon, S., et al. (2025-06-10). "Integration of AI and ML in Tuberculosis (TB) Management"**
- **–ñ—É—Ä–Ω–∞–ª:** Frontiers in Pharmacology
- **–û—Ö–≤–∞—Ç—ã–≤–∞–µ—Ç:**
  - –î–∏–∞–≥–Ω–æ—Å—Ç–∏–∫–∞ –¢–ë (CXR analysis —Å CNN, GeneXpert, CRISPR)
  - –õ–µ—á–µ–Ω–∏–µ: –ø—Ä–æ–≥–Ω–æ–∑ –∏—Å—Ö–æ–¥–æ–≤ (SVMs, Random Forests, CNNs)
  - –õ–µ–∫–∞—Ä—Å—Ç–≤–µ–Ω–Ω–∞—è —É—Å—Ç–æ–π—á–∏–≤–æ—Å—Ç—å: –ø—Ä–µ–¥—Å–∫–∞–∑–∞–Ω–∏–µ MDR/XDR
  - Digital adherence technologies (AI –¥–ª—è –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥–∞)
- **–î–ª—è –¢–ë drug discovery:** –ö–æ–Ω—Ç–µ–∫—Å—Ç MDR-TB, –∫–∞–∫–∏–µ —à—Ç–∞–º–º—ã —Å—É—â–µ—Å—Ç–≤—É—é—Ç
- **–ò–Ω—Ç–µ—Ä–µ—Å–Ω–æ:** CRISPR-based detection + ML –¥–ª—è rapid diagnostics

---

## –ß–∞—Å—Ç—å 2: –°–ü–ï–¶–ò–ê–õ–ò–ó–ò–†–û–í–ê–ù–ù–´–ï –°–¢–ê–¢–¨–ò

### –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–π –¥–∏–∑–∞–π–Ω & QSAR

#### 11. **Ekins, S., et al. (2019). "Machine Learning and AI for ADME Modeling."**
- **–ñ—É—Ä–Ω–∞–ª:** Molecular Pharmaceutics
- **Focus:** ADME properties (Absorption, Distribution, Metabolism, Excretion)
- **–î–ª—è –¢–ë:** Lipophilicity, TPSA, CYP450 metabolism, lung penetration

#### 12. **Gupta, R., et al. (2023). "Machine Learning in Drug Discovery: A Review."**
- **–ñ—É—Ä–Ω–∞–ª:** Journal of Chemical Information and Modeling
- **–û—Ö–≤–∞—Ç—ã–≤–∞–µ—Ç:** –í—Å–µ –∞—Å–ø–µ–∫—Ç—ã –æ—Ç target ID –¥–æ clinical trials

#### 13. **Chen, H., et al. (2018). "The rise of deep learning in drug discovery."**
- **–ñ—É—Ä–Ω–∞–ª:** Drug Discovery Today
- **–ò—Å—Ç–æ—Ä–∏—á–µ—Å–∫–∏–π –∫–æ–Ω—Ç–µ–∫—Å—Ç:** –ö–∞–∫ DL —Ç—Ä–∞–Ω—Å—Ñ–æ—Ä–º–∏—Ä–æ–≤–∞–ª drug discovery

#### 14. **Lavecchia, A. (2019). "Deep learning in drug discovery."**
- **–ñ—É—Ä–Ω–∞–ª:** Drug Discovery Today
- **–ü—Ä–∞–∫—Ç–∏—á–µ—Å–∫–∏–µ –ø—Ä–∏–º–µ—Ä—ã:** CNN –¥–ª—è –¥–æ–∑–∏–Ω–≥–∞, RNN –¥–ª—è SMILES

---

### AlphaFold & –°—Ç—Ä—É–∫—Ç—É—Ä–Ω–∞—è –±–∏–æ–ª–æ–≥–∏—è

#### 15. **AlphaFill: –∏–Ω—Ç–µ–≥—Ä–∞—Ü–∏—è co-factors –≤ AlphaFold —Å—Ç—Ä—É–∫—Ç—É—Ä—ã**
- **URL:** alphafill.eu
- **–ü—Ä–æ–±–ª–µ–º–∞:** AF models are "protein-only" (–±–µ–∑ –ª–∏–≥–∞–Ω–¥–æ–≤)
- **–†–µ—à–µ–Ω–∏–µ:** Homology-based algorithm "transplants" co-factors
- **–î–ª—è –¢–ë:** –£–ª—É—á—à–µ–Ω–∏–µ AF —Å—Ç—Ä—É–∫—Ç—É—Ä InhA, rpoB –¥–ª—è –¥–æ–∑–∏–Ω–≥–∞

#### 16. **Kuznetsov, M., et al. (2024-04-25). "COSMIC: Molecular Conformation Space Modeling..."**
- **–ñ—É—Ä–Ω–∞–ª:** ACS Journal of Chemical Information and Modeling
- **–ß—Ç–æ —ç—Ç–æ:** GAN –¥–ª—è –º–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã—Ö –∫–æ–Ω—Ñ–æ—Ä–º–∞—Ü–∏–π
- **–î–∞–Ω–Ω—ã–µ:** GEOM-QM9 (33M —Å—Ç—Ä—É–∫—Ç—É—Ä), GEOM-Drugs
- **–î–ª—è –¢–ë:** –ì–µ–Ω–µ—Ä–∞—Ü–∏—è 3D –∫–æ–Ω—Ñ–æ—Ä–º–∞—Ü–∏–π –¥–ª—è –¥–æ–∑–∏–Ω–≥–∞

---

### Multi-modal & Interpretability

#### 17. **Li, Y., et al. (2024-05-22). "Image-based molecular representation learning..."**
- **–ñ—É—Ä–Ω–∞–ª:** Oxford Briefings in Bioinformatics
- **–ú–µ—Ç–æ–¥:** 2D images –º–æ–ª–µ–∫—É–ª ‚Üí CNN –∏–ª–∏ Vision Transformer
- **–†–µ–∑—É–ª—å—Ç–∞—Ç:** F1 score 97-98% –¥–ª—è reconstruction
- **–î–ª—è –¢–ë:** –ê–ª—å—Ç–µ—Ä–Ω–∞—Ç–∏–≤–Ω–æ–µ –ø—Ä–µ–¥—Å—Ç–∞–≤–ª–µ–Ω–∏–µ –º–æ–ª–µ–∫—É–ª

#### 18. **XAI –≤ drug discovery (–æ–±–æ–±—â–µ–Ω–∏–µ)**
- **–ú–µ—Ç–æ–¥—ã:** SHAP, LIME, attention visualization, saliency maps
- **–ü–æ—á–µ–º—É –≤–∞–∂–Ω–æ:** –•–∏–º–∏–∫–∏ —Ö–æ—Ç—è—Ç –ø–æ–Ω–∏–º–∞—Ç—å, —á—Ç–æ –¥–µ–ª–∞–µ—Ç –º–æ–ª–µ–∫—É–ª—É –∞–∫—Ç–∏–≤–Ω–æ–π
- **–î–ª—è –¢–ë:** –û–±—ä—è—Å–Ω–∏—Ç—å: –∫–∞–∫–∏–µ –∞—Ç–æ–º—ã/–≥—Ä—É–ø–ø—ã –Ω—É–∂–Ω—ã –¥–ª—è –∏–Ω–≥–∏–±–∏—Ä–æ–≤–∞–Ω–∏—è InhA

---

## –ß–∞—Å—Ç—å 3: –¢–ï–ö–£–©–ò–ï –¢–†–ï–ù–î–´ (2024-2025 PUBLICATION SURGE)

### 3.1 –°—Ç–∞—Ç–∏—Å—Ç–∏–∫–∞ –∏–∑ Scopus Database

**–ò–∑ —Å—Ç–∞—Ç—å–∏ "2024: The year AI drug discovery took center stage":**

```
PUBLICATION STATISTICS (2019-2024):

AI Drug Discovery:
  2019: 220 papers
  2024: ~1,147 papers (estimated)
  Growth: 421% (CAGR 39%)
  % of all AI pharma: 11%

AI Protein Structure Prediction:
  2019: 561 papers
  2024: ~1,726 papers
  Growth: 208% (CAGR 25%)
  % of all AI pharma: 17%

Clinical Trial AI:
  2024: ~7,442 papers
  Growth: 444% since 2019
  % of all AI pharma: 72%

KEY INSIGHT: Drug discovery –±–æ–ª–µ–µ –æ—Ç—Å—Ç–∞–µ—Ç –æ—Ç clinical AI
‚Üí –í–û–ó–ú–û–ñ–ù–û–°–¢–¨ –¥–ª—è –≤–∞—à–µ–≥–æ PhD!
```

### 3.2 FDA Approvals with AI (2016-2023)

- **–í—Å–µ–≥–æ FDA –æ–¥–æ–±—Ä–µ–Ω–∏–π —Å AI –∫–æ–º–ø–æ–Ω–µ–Ω—Ç–æ–º:** >500
- **–ò–∑ –Ω–∏—Ö:** ~50 –æ—Å–Ω–æ–≤–∞–Ω—ã –Ω–∞ ML –º–æ–¥–µ–ª—è—Ö –¥–ª—è target/lead discovery
- **–¢—Ä–µ–Ω–¥:** –†–∞—Å—Ç–µ—Ç —ç–∫—Å–ø–æ–Ω–µ–Ω—Ü–∏–∞–ª—å–Ω–æ

---

## –ß–∞—Å—Ç—å 4: –ë–ê–ó–´ –î–ê–ù–ù–´–• –ò –ò–ù–°–¢–†–£–ú–ï–ù–¢–´

### A. –ü—É–±–ª–∏—á–Ω—ã–µ –±–∞–∑—ã –¥–∞–Ω–Ω—ã—Ö

| –ë–î | URL | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ | –¢–ë –ø—Ä–∏–º–µ–Ω–µ–Ω–∏–µ |
|----|-----|-----------|--------------|
| **ChEMBL** | www.ebi.ac.uk/chembl | 2M+ —Å–æ–µ–¥–∏–Ω–µ–Ω–∏–π, 15M+ –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–µ–π | –û–°–ù–û–í–ù–ê–Ø –¥–ª—è –¢–ë –∏–Ω–≥–∏–±–∏—Ç–æ—Ä–æ–≤ |
| **PubChem** | pubchem.ncbi.nlm.nih.gov | 110M+ –º–æ–ª–µ–∫—É–ª | –í–∞–ª–∏–¥–∞—Ü–∏—è, —Ä–∞—Å—à–∏—Ä–µ–Ω–∏–µ –¥–∞—Ç–∞—Å–µ—Ç–∞ |
| **ZINC** | zinc.docking.org | 230M+ –¥–ª—è –¥–æ–∑–∏–Ω–≥–∞ | Virtual screening –º–æ–ª–µ–∫—É–ª |
| **DrugBank** | go.drugbank.com | 13k+ approved/experimental | –ú–µ—Ö–∞–Ω–∏–∑–º –¥–µ–π—Å—Ç–≤–∏—è, ADME |
| **TB Alliance DB** | tballiance.org | –¢–ë-—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ | –ì–õ–ê–í–ù–´–ô –ò–°–¢–û–ß–ù–ò–ö |
| **StreptomycinDB** | tb.fli-leibniz.de | Mtb —Å—Ç—Ä—É–∫—Ç—É—Ä—ã + –∏–Ω–≥–∏–±–∏—Ç–æ—Ä—ã | –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–π –¥–∏–∑–∞–π–Ω |
| **PDB** | rcsb.org | 200k+ protein structures | –°—Ç—Ä—É–∫—Ç—É—Ä—ã –º–∏—à–µ–Ω–µ–π |
| **AlphaFold DB** | alphafold.ebi.ac.uk | 200M+ predicted —Å—Ç—Ä—É–∫—Ç—É—Ä | –ù–æ–≤—ã–µ –º–∏—à–µ–Ω–∏ Mtb |
| **Mycobrowser** | mycobrowser.epfl.ch | Genome Mtb H37Rv | –ú—É—Ç–∞—Ü–∏–∏, —Ä–µ–∑–∏—Å—Ç–µ–Ω—Ç–Ω–æ—Å—Ç—å |

### B. –í–µ–±-–∏–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç—ã –¥–ª—è ADME

| –ò–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç | URL | –§—É–Ω–∫—Ü–∏—è | –ë–µ—Å–ø–ª–∞—Ç–Ω–æ |
|------------|-----|---------|----------|
| **ADMETlab 2.0** | admetmesh.scbdd.com | ADME/Tox prediction | ‚úÖ –î–∞ |
| **pkcsm** | biosig.unimelb.edu.au/pkcsm | Pharmacokinetic properties | ‚úÖ –î–∞ |
| **SwissADME** | www.swissadme.ch | ADME filtering | ‚úÖ –î–∞ |
| **Pred Halo** | webservices.gpa.ethz.ch | Activity prediction | ‚úÖ –î–∞ |

### C. –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–π –¥–∏–∑–∞–π–Ω –∏–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç—ã

| –ò–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç | –¢–∏–ø | URL | –¶–µ–Ω–∞ |
|------------|-----|-----|------|
| **AutoDock Vina** | –î–æ–∑–∏–Ω–≥ | autodock.scripps.edu | –ë–µ—Å–ø–ª–∞—Ç–Ω–æ |
| **GNINA** | GPU –¥–æ–∑–∏–Ω–≥ | github.com/gnina/gnina | –ë–µ—Å–ø–ª–∞—Ç–Ω–æ |
| **PyMOL** | –í–∏–∑—É–∞–ª–∏–∑–∞—Ü–∏—è | pymol.org | –ë–µ—Å–ø–ª–∞—Ç–Ω–æ (edu) |
| **Schrodinger Maestro** | Premium –¥–æ–∑–∏–Ω–≥ | schrodinger.com | $10k/–≥–æ–¥ (–ª—É—á—à–µ free alternative) |
| **OpenMM** | –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω–∞—è –¥–∏–Ω–∞–º–∏–∫–∞ | openmm.org | –ë–µ—Å–ø–ª–∞—Ç–Ω–æ |

---

## –ß–∞—Å—Ç—å 5: –†–ï–ö–û–ú–ï–ù–î–£–ï–ú–´–ï –ö–£–†–°–´ & –û–ë–£–ß–ï–ù–ò–ï

### A. YouTube & Free Resources

- **StatQuest with Josh Starmer:** ML basics (–±–µ–∑ –ª–∏—à–Ω–µ–π —Å–ª–æ–∂–Ω–æ—Å—Ç–∏)
- **Andrew Ng - Machine Learning:** Coursera (–∫–ª–∞—Å—Å–∏–∫–∞)
- **Hugging Face Course:** –¢—Ä–∞–Ω—Å—Ñ–æ—Ä–º–µ—Ä—ã + NLP
- **RDKit Official Tutorials:** –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω–∞—è —Ö–∏–º–∏—è
- **PyTorch Tutorials:** –ì–ª—É–±–æ–∫–æ–µ –æ–±—É—á–µ–Ω–∏–µ
- **Kaggle:** Drug discovery datasets + competitions

### B. –ü–ª–∞—Ç–Ω—ã–µ –∫—É—Ä—Å—ã (–µ—Å–ª–∏ –Ω—É–∂–Ω–∞ —Å—Ç—Ä—É–∫—Ç—É—Ä–∞)

- **Coursera: "Deep Learning Specialization"** ($40-50/–º–µ—Å)
- **LinkedIn Learning:** Computational chemistry, drug discovery
- **Udemy:** PyTorch, Transformers, Drug Discovery

### C. University Courses (–µ—Å–ª–∏ –µ—Å—Ç—å –¥–æ—Å—Ç—É–ø)

- **MIT OpenCourseWare:** Cheminformatics, Drug Discovery
- **Stanford:** CS224W (Graph Neural Networks)
- **Cambridge:** Computational Chemistry

---

## –ß–∞—Å—Ç—å 6: –ö–ê–ö –ò–°–ü–û–õ–¨–ó–û–í–ê–¢–¨ –≠–¢–ò –ò–°–¢–û–ß–ù–ò–ö–ò

### –î–ª—è –ª–∏—Ç–µ—Ä–∞—Ç—É—Ä–Ω–æ–≥–æ –æ–±–∑–æ—Ä–∞ –≤–∞—à–µ–π –¥–∏—Å—Å–µ—Ä—Ç–∞—Ü–∏–∏:

**–†–∞–∑–¥–µ–ª 1: –°–æ–≤—Ä–µ–º–µ–Ω–Ω—ã–µ –º–µ—Ç–æ–¥—ã –æ—Ä–≥–∞–Ω–∏—á–µ—Å–∫–æ–π —Ö–∏–º–∏–∏**
- –ò—Å–ø–æ–ª—å–∑—É–π—Ç–µ: Lavecchia (2019), Chen (2018)
- –î–æ–±–∞–≤—å—Ç–µ: –°–∏–Ω—Ç–µ–∑ —Ç–µ—Ö–Ω–æ–ª–æ–≥–∏–∏, Green chemistry

**–†–∞–∑–¥–µ–ª 2: Machine Learning –º–µ—Ç–æ–¥—ã**
- QSAR: Hung et al. (2021), Gupta et al. (2023)
- GNN: Wang et al. (2025), Noor et al. (2024)
- –ì–µ–Ω–µ—Ä–∞—Ü–∏—è: Khater et al. (2025)
- –¢—Ä–∞–Ω—Å—Ñ–æ—Ä–º–µ—Ä—ã: (–Ω–∞–π—Ç–∏ –∏–∑ Hugging Face)

**–†–∞–∑–¥–µ–ª 3: –°—Ç—Ä—É–∫—Ç—É—Ä–Ω–æ–µ –ø—Ä–µ–¥—Å–∫–∞–∑–∞–Ω–∏–µ**
- AlphaFold: Desai et al. (2024)
- –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω–∞—è –¥–∏–Ω–∞–º–∏–∫–∞: Kuznetsov et al. (2024)

**–†–∞–∑–¥–µ–ª 4: –¢–ë-—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω—ã–µ –ø–æ–¥—Ö–æ–¥—ã**
- –û—Å–Ω–æ–≤–∞: "TB Drug Discovery in AI age" (2025) + Memon et al. (2025)
- –ú–∏—à–µ–Ω–∏: TB Alliance resources

**–†–∞–∑–¥–µ–ª 5: ADME & Toxicity**
- Ekins et al. (2019)
- Li et al. (2024) - image-based methods

**–†–∞–∑–¥–µ–ª 6: –ò–Ω—Ç–µ–≥—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–π pipeline**
- Vamathevan et al. (2019) - —à–∞–±–ª–æ–Ω
- Stokes et al. (2020) - case study —É—Å–ø–µ—Ö–∞

---

## –ò—Ç–æ–≥–æ–≤–∞—è —Å–∏—Å—Ç–µ–º–∞ —Ü–∏—Ç–∏—Ä–æ–≤–∞–Ω–∏—è –¥–ª—è –¥–∏—Å—Å–µ—Ä—Ç–∞—Ü–∏–∏

```
–†–ï–ö–û–ú–ï–ù–î–£–ï–ú–û–ï –ö–û–õ–ò–ß–ï–°–¢–í–û –ò–°–¢–û–ß–ù–ò–ö–û–í:

–†–∞–∑–¥–µ–ª –≤–≤–µ–¥–µ–Ω–∏—è: 30-50 –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤
  - –û–±–∑–æ—Ä—ã (reviews): 10-15
  - –û—Ä–∏–≥–∏–Ω–∞–ª—å–Ω—ã–µ —Å—Ç–∞—Ç—å–∏: 15-20
  - –ö–ª–∞—Å—Å–∏—á–µ—Å–∫–∏–µ —Ä–∞–±–æ—Ç—ã (2010-2016): 5-10
  - –ù–æ–≤–µ–π—à–∏–µ (2024-2025): 5-8

–†–∞–∑–¥–µ–ª –º–µ—Ç–æ–¥–æ–ª–æ–≥–∏—è: 20-30 –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤
  - –ú–µ—Ç–æ–¥–∏—á–µ—Å–∫–∏–µ —Å—Ç–∞—Ç—å–∏: 10-15
  - –î–æ–∫—É–º–µ–Ω—Ç–∞—Ü–∏—è (RDKit, PyTorch): 5
  - Case studies: 5-10

–†–∞–∑–¥–µ–ª —Ä–µ–∑—É–ª—å—Ç–∞—Ç—ã: 20-40 –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤ (–ø–æ –º–µ—Ä–µ –Ω–µ–æ–±—Ö–æ–¥–∏–º–æ—Å—Ç–∏)

–†–∞–∑–¥–µ–ª –æ–±—Å—É–∂–¥–µ–Ω–∏—è: 30-50 –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤

–ò–¢–û–ì–û: 100-150 –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤ (—Ç–∏–ø–∏—á–Ω–æ –¥–ª—è PhD –¥–∏—Å—Å–µ—Ä—Ç–∞—Ü–∏–∏)
```

---

**–î–æ–∫—É–º–µ–Ω—Ç –ø–æ–¥–≥–æ—Ç–æ–≤–ª–µ–Ω:** –î–µ–∫–∞–±—Ä—å 2025  
**–û–±–Ω–æ–≤–ª–µ–Ω–æ:** –ü–æ—Å–ª–µ–¥–Ω–∏–µ –ø—É–±–ª–∏–∫–∞—Ü–∏–∏ –¥–æ –¥–µ–∫–∞–±—Ä—è 2025  
**–°—Ç–∞—Ç—É—Å:** –ì–æ—Ç–æ–≤ –¥–ª—è –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏—è –≤ PhD –¥–∏—Å—Å–µ—Ä—Ç–∞—Ü–∏–∏

---

## –ë–´–°–¢–†–´–ô –°–¢–ê–†–¢ –°–ï–ì–û–î–ù–Ø

1. **–ü—Ä–æ—á–∏—Ç–∞–π—Ç–µ –°–†–ê–ó–£:**
   - Stokes et al. (2020) - 30 –º–∏–Ω—É—Ç
   - "TB Drug Discovery in AI age" (2025) - 1 —á–∞—Å
   - Vamathevan et al. (2019) - 1 —á–∞—Å

2. **–£—Å—Ç–∞–Ω–æ–≤–∏—Ç–µ –°–ï–ô–ß–ê–°:**
   ```bash
   pip install rdkit pandas numpy scikit-learn torch pytorch-geometric
   ```

3. **–ó–∞–≥—Ä—É–∑–∏—Ç–µ –°–ï–ì–û–î–ù–Ø:**
   - ChEMBL InhA –∏–Ω–≥–∏–±–∏—Ç–æ—Ä—ã (CSV)
   - PDB —Å—Ç—Ä—É–∫—Ç—É—Ä—É InhA (1ENX)
   - AlphaFold DB —Å—Ç—Ä—É–∫—Ç—É—Ä—É

4. **–ó–∞–ø—É—Å—Ç–∏—Ç–µ –ó–ê–í–¢–†–ê:**
   - –ü–µ—Ä–≤—É—é QSAR –º–æ–¥–µ–ª—å (scikit-learn)
   - –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–π –¥–æ–∑–∏–Ω–≥ (AutoDock Vina)

üöÄ **–í–ø–µ—Ä–µ–¥ –≤ PhD!**
